arrow
H

How-Wen Ko

chang gung memorial hospital
H指数:9
被引数:213

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis

临床特征和接受达可替尼45或30 mg起始剂量治疗的晚期EGFR突变非小细胞肺癌的结局:一项回顾性多中心分析

2026-06-250
PRE
Clinical outcome analysis of different first- and second-generation EGFR-tyrosine kinase inhibitors in untreated patients with EGFR-mutated non-small cell lung cancer with baseline brain metastasis

EGFR突变非小细胞肺癌伴基线脑转移患者中,不同一代和二代EGFR酪氨酸激酶抑制剂的临床疗效分析

2025-02-260
OA
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity

I类HLA等位基因与奥希替尼诱导的超敏反应风险增加相关

2025-01-010
PRE
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma
2022-11-167
PRE